Compare IDT & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | CMPS |
|---|---|---|
| Founded | 1990 | 2020 |
| Country | United States | United Kingdom |
| Employees | 1925 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | 2020 |
| Metric | IDT | CMPS |
|---|---|---|
| Price | $58.88 | $13.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $80.00 | $25.38 |
| AVG Volume (30 Days) | 223.5K | ★ 3.2M |
| Earning Date | 06-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.72 | $3.25 |
| 52 Week High | $71.05 | $15.40 |
| Indicator | IDT | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 64.90 | 59.15 |
| Support Level | $50.83 | $5.57 |
| Resistance Level | N/A | $14.76 |
| Average True Range (ATR) | 1.90 | 0.96 |
| MACD | 0.36 | 0.06 |
| Stochastic Oscillator | 92.67 | 61.18 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.